Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Shire Plc executes agreement to divest DERMAGRAFT


Friday, 17 Jan 2014 02:00am EST 

Shire Plc:Says has entered into a definitive agreement pursuant to which it has sold its DERMAGRAFT assets to Organogenesis Inc.Says DERMAGRAFT is a living skin substitute indicated for use in the treatment of full-thickness diabetic foot ulcers and is approved for use in the US and Canada.Says Going forward Organogenesis will assume all financial and management responsibility for DERMAGRAFT. 

Company Quote

185.8
1.21 +0.66%
4:00pm EDT